Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Wijns W) srt2:(2010-2014)"

Sökning: WFRF:(Wijns W) > (2010-2014)

  • Resultat 11-14 av 14
  • Föregående 1[2]
Sortera/gruppera träfflistan
  • Rydén, Lars, et al. (författare)
  • ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
  • 2013
  • Ingår i: European Heart Journal. - 0195-668X .- 1522-9645. ; 34:39, s. 3035-3087
  • Tidskriftsartikel (refereegranskat)abstract
    • This is the second iteration of the European Society of Cardiology (ESC) and European Association for the Study of Diabetes (EASD) joining forces to write guidelines on the management of diabetes mellitus (DM), pre-diabetes, and cardiovascular disease (CVD), designed to assist clinicians and other healthcare workers to make evidence-based management decisions. The growing awareness of the strong biological relationship between DM and CVD rightly prompted these two large organizations to collaborate to generate guidelines relevant to their joint interests, the first of which were published in 2007. Some assert that too many guidelines are being produced but, in this burgeoning field, five years in the development of both basic and clinical science is a long time and major trials have reported in this period, making it necessary to update the previous Guidelines.
  • Saito, S, et al. (författare)
  • A randomized, prospective, intercontinental evaluation of a bioresorbable polymer sirolimus-eluting coronary stent system : the CENTURY II (Clinical Evaluation of New Terumo Drug-Eluting Coronary Stent System in the Treatment of Patients with Coronary Artery Disease) trial
  • 2014
  • Ingår i: European Heart Journal. - 0195-668X .- 1522-9645. ; 35:30, s. 2021-2031
  • Tidskriftsartikel (refereegranskat)abstract
    • Aim The aim of this study was to establish safety and efficacy of a new sirolimus-eluting stent with bioresorbable polymer, Ultimaster (BP-SES). Sirolimus-eluting stent with bioresorbable polymer was compared with everolimus-eluting, permanent polymer, Xience stent (PP-EES) in the frame of a CENTURY II clinical trial designed to make global clinical data compliant with regulatory requirements in Europe and Japan.Methods and results The CENTURY II is a prospective, multicentre, randomized (1 : 1), single blind, controlled, non-inferiority clinical trial conducted at 58 study sites in Japan, Europe, and Korea. A total of 1123 patients requiring a percutaneous coronary intervention (PCI) procedure, with implantation of drug-eluting stent (DES), were enrolled [total population (TP)]. Randomization of patients was stratified for the subset of patients matching requirements for DES in Japan (Cohort JR, n = 722). Baseline patient demographic and angiographic characteristics were similar in both study arms, with minimal differences between the TP and Cohort JR. The primary endpoint, freedom from target lesion failure (TLF) at 9 months—TLF [composite of cardiac death, target-vessel-related myocardial infarction (MI) and target lesion revascularization]—was 95.6% with BP-SES and 95.1% with PP-EES (Pnon-inferiority<0.0001). Composite of cardiac death and MI rate was 2.9 and 3.8% (P = 0.40) and target vessel revascularization was 4.5% with BP-SES and 4.2% with PP-EES (P = 0.77). The stent thrombosis rate was 0.9% in both arms. In Cohort JR, freedom from TLF was 95.9 and 94.6% (Pnon-inferiority < 0.0005) with BP-SES and PP-EES, respectively.Conclusion The new bioresorbable polymer sirolimus-eluting stent showed safety and efficacy profiles similar to durable polymer everolimus-eluting stent at 9-month follow-up.
  • Wijns, W, et al. (författare)
  • Myocardial revascularization
  • 2011
  • Ingår i: REVISTA PORTUGUESA DE CARDIOLOGIA. - 0870-2551. ; 30:12, s. 951-1005
  • Tidskriftsartikel (övrigt vetenskapligt)
Skapa referenser, mejla, bekava och länka
  • Resultat 11-14 av 14
  • Föregående 1[2]
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy